Drug Profile
Research programme: lung disorder therapeutics - OrPro Therapeutics
Alternative Names: TheraduxLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator National Jewish Medical and Research Center
- Developer OrPro Therapeutics
- Class Recombinant proteins
- Mechanism of Action Thioredoxin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis; Lung disorders
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (Inhalation, Aerosol)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Lung-disorders in USA (Inhalation, Aerosol)
- 03 Jun 2020 Preclinical development is ongoing in USA (Inhalation)